EIM

AngioDynamics, Inc.

Fundamental data last updated:July 14, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

07/21/2026

Business Summary

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

 


VALUATION

P/E

-15.55

Market Cap ($M USD)

$484.67M

Forward P/E

40.45

PEG

0.29

PRICE TO SALES

1.54

PRICE TO BOOK

2.81

EV / EBITDA

-114.93

5-Year Average P/E

Free Cash Flow Yield

0.31%

DCF Value

$2.75

Graham Number

N/A

Price to FCF

322.47

EV to FCF

297.31

Earnings Yield

-6.43%

FCF Yield

0.31%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.75

Next Year EPS Growth Estimate

$0.29

Next Year Revenue Growth Estimate

$39.16B

Return on Equity (ROE)

-17.65%

FREE CASH FLOW

Operating Margin

-8.08%

Debt-to-Equity

0.00

Piotroski F-Score

4

Altman Z-Score

2.19

Return on Invested Capital (ROIC)

-13.03%

Current Ratio

2.35

Quick Ratio

1.47

Net Debt to EBITDA

9.72

Interest Coverage

-130.74

Gross Profit margin

53.45%

FCF PER SHARE

$0.04

REVENUE PER SHARE

$7.54

Gainseekers Quantitative Analysis

Summary

AngioDynamics, Inc. presents a perplexing valuation scenario. Despite a market cap suggesting significant scale, the stock traded well below its DCF value, indicating potential undervaluation. However, a Forward P/E of 38.62 and a negative Earnings Yield highlight a disconnect between current earnings and future expectations. The Altman Z-score of 2.01 suggests moderate financial distress, raising questions about its long-term viability. Investors should be wary of the company’s ability to deliver growth amidst these mixed signals.

AI Exposure / Tech Reliance

Operating within the Medical Instruments & Supplies industry, AngioDynamics is well-positioned to leverage AI and tech advancements. The healthcare sector's increasing reliance on data-driven solutions offers a fertile ground for innovation. As AI continues to transform medical diagnostics and treatment, the company could capitalize on these shifts to enhance its product offerings.

The Bull Case

For the value-driven investor, AngioDynamics offers intriguing prospects. The PEG Forward ratio of 0.28 suggests the stock is undervalued relative to its growth potential. Despite a negative ROIC, the company's zero debt and a Piotroski F-Score of 4 indicate some operational resilience. Its gross profit margin of 53.45% underscores strong pricing power, hinting at the ability to maintain profitability in a competitive market.

The Bear Case

Yet, the bear case is hard to ignore. AngioDynamics struggles with a negative EPS and an alarming EV to EBITDA ratio of -109.30, reflecting severe profitability issues. The Price to FCF ratio of 307.90 signals that investors are paying a premium for limited cash flow. With the stock extended near its 52-week high, the risk of overvaluation looms large, especially given its weak operating margin of -8.08%.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$16.50

Institutional Ownership %

1-Year Beta

0.37

Insider Buying % (6 Mo)

Distance to 52-Week High

19.27%

Distance to 52-Week Low

28.73%

EARNINGS SURPRISE %

36.36%

50-DAY SMA

$10.92

200-DAY SMA

$11.23

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.